Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study

The phase I/II AU‐003 study in patients with treatment‐naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma demonstrated that zanubrutinib therapy results in clinically meaningful and durable responses with acceptable safety and tolerability. We report upd...

Descripción completa

Detalles Bibliográficos
Autores principales: Cull, Gavin, Burger, Jan A., Opat, Stephen, Gottlieb, David, Verner, Emma, Trotman, Judith, Marlton, Paula, Munoz, Javier, Johnston, Patrick, Simpson, David, Stern, Jennifer C., Prathikanti, Radha, Wu, Kenneth, Novotny, William, Huang, Jane, Tam, Constantine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy–Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300083/
https://www.ncbi.nlm.nih.gov/pubmed/34915592
http://dx.doi.org/10.1111/bjh.17994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300083/
https://www.ncbi.nlm.nih.gov/pubmed/34915592
http://dx.doi.org/10.1111/bjh.17994

Ejemplares similares